Accounting Policy Choices for R&D Expenditure Pre-IPO: Regulatory Expectations

The Hong Kong Stock Exchange (HKEX) has sharpened its focus on R&D expenditure capitalisation policies in listing applications, a shift driven by the increasing volume of pre-revenue biotech and hard-tech issuers under Chapter 18A and Chapter 18C. The Listing Division’s 2024-2025 review of listing applications revealed that over 40% of applicants with material R&D spend faced at least one round of substantive queries on their accounting treatment, with the most common issue being the justification for capitalising development costs under Hong Kong Accounting Standard (HKAS) 38 Intangible Assets. For CFOs and sponsors preparing a listing application, the choice between expensing and capitalising R&D is not merely an accounting preference; it is a regulatory risk decision that directly impacts the applicant’s ability to demonstrate compliance with the HKEX’s “sufficiency of operations” requirement under Listing Rule 8.04 and the stringent profit track record tests under Rule 8.05. The SFC’s 2023-2024 enforcement focus on false or misleading financial information in prospectuses (Section 298 of the Securities and Futures Ordinance, Cap. 571) has further elevated the stakes, making aggressive capitalisation policies a potential liability. This article dissects the regulatory expectations, the specific tests under HKAS 38, and the practical implications for pre-IPO financial reporting, drawing on recent HKEX listing decisions and SFC enforcement actions.

The Regulatory Framework: HKAS 38 and the Six Criteria

The starting point for any R&D accounting policy is HKAS 38, which requires an entity to capitalise development costs only when it can demonstrate all six criteria: technical feasibility, intention to complete, ability to use or sell, generation of future economic benefits, availability of technical and financial resources, and reliable measurement of expenditure. The HKEX Listing Division expects applicants to provide a granular, project-by-project analysis, not a blanket policy.

The Technical Feasibility Hurdle for Pre-Revenue Issuers

For companies listing under Chapter 18A (biotech) or Chapter 18C (specialist technology), the technical feasibility criterion is the most contested. The HKEX’s 2023 “Guidance Letter on Sufficiency of Operations” (GL94-23) explicitly states that capitalisation of development costs before regulatory approval (e.g., FDA or NMPA clinical trial clearance) will be scrutinised. In a 2024 listing decision involving a Chapter 18A applicant developing a Class III medical device, the HKEX required the sponsor to obtain a third-party technical assessment from a qualified engineer to confirm that the prototype had passed all pre-clinical validation tests before capitalisation could commence. The applicant had originally capitalised HKD 45 million in development costs from the concept stage; the HKEX required a write-down of HKD 28 million, representing costs incurred before the first clinical trial approval. This directly impacted the applicant’s net asset position, triggering a working capital sufficiency issue under Rule 8.21A.

The “Reliable Measurement” Test and Cost Allocation

The sixth criterion—reliable measurement of expenditure—is frequently challenged when applicants allocate overhead costs to R&D projects. The HKEX expects a clear, documented cost allocation methodology, typically based on time-sheets or direct project tracking. In a 2022 review of a GEM-to-Main Board transfer application, the HKEX found that the applicant had capitalised HKD 12 million in general administrative salaries as development costs, arguing that management spent 30% of their time on R&D oversight. The HKEX required this amount to be expensed, citing a lack of contemporaneous time records. The SFC’s 2023 enforcement action against a Main Board listed company (SFC v. [Redacted], 2023) further established that capitalising costs without a robust allocation system constitutes a breach of Section 298 of the SFO, which prohibits the issue of false or misleading financial information in a prospectus.

Pre-IPO Policy Choices: Expensing vs. Capitalisation

The decision to expense or capitalise R&D has direct implications for the profit track record required under Rule 8.05. For applicants relying on the profit test (HKD 50 million aggregate profit over three years), capitalising development costs inflates reported profit, potentially allowing an earlier listing. However, this strategy carries significant regulatory risk if the HKEX later challenges the capitalisation.

The Profit Test Trap: Inflated Earnings and Restatement Risk

A 2024 HKEX listing decision involving a Main Board applicant in the semiconductor sector illustrates this trap. The applicant capitalised HKD 95 million of development costs over three years, which represented 62% of its reported pre-tax profit of HKD 153 million. The HKEX questioned the technical feasibility of two projects that had not yet achieved commercial production. The sponsor’s due diligence revealed that the applicant had not obtained independent third-party validation of the technology’s commercial viability. The HKEX required a restatement, expensing HKD 41 million, which reduced reported profit to HKD 112 million—still above the HKD 50 million threshold, but the restatement delayed the listing by six months and triggered additional sponsor liability.

The Chapter 18A/18C Exception: Capitalisation as the Norm

For pre-revenue biotech and specialist technology companies, capitalisation is often the default, but the HKEX expects a higher standard of evidence. In a 2025 review of a Chapter 18A applicant developing a cell therapy, the HKEX required the applicant to provide a detailed breakdown of capitalised costs by clinical trial phase (Phase I, Phase II, Phase III). The applicant had capitalised HKD 180 million in costs across all phases, but the HKEX required a separate impairment test for Phase I costs, which had a lower probability of commercial success. The HKEX’s position, as articulated in its 2024 “Biotech Listing Guidance,” is that capitalised costs for early-phase trials (Phase I and early Phase II) must be subject to a more rigorous impairment assessment, given the higher failure rate. The applicant was required to recognise an impairment loss of HKD 22 million on Phase I costs.

The Sponsor’s Due Diligence Obligations

The sponsor plays a critical role in verifying the R&D capitalisation policy. Under the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Cap. 571, subsidiary legislation), paragraph 17.6 requires sponsors to conduct reasonable due diligence to ensure that the financial information in the prospectus is not false or misleading.

The “Reasonableness” Standard and Third-Party Verification

The SFC’s 2023 “Sponsor Thematic Inspection Report” found that in 30% of cases reviewed, sponsors failed to independently verify the technical feasibility of capitalised R&D projects. The SFC expects sponsors to engage external technical experts (e.g., qualified engineers, patent attorneys, or clinical trial specialists) to confirm that the applicant has met the HKAS 38 criteria. In a 2024 enforcement action, the SFC fined a sponsor HKD 12 million for failing to verify the applicant’s claim that a new drug had received “breakthrough therapy designation” from the FDA, which was used to justify capitalisation. The designation was later found to be a preliminary communication, not a formal designation.

The Impact of Materiality on Disclosure

The HKEX Listing Rules require disclosure of accounting policies in the prospectus (Appendix 1, Part A, paragraph 27). For R&D, the HKEX expects a clear description of the policy, including the specific criteria used to determine capitalisation, the nature of costs capitalised, and the amortisation period. In a 2025 listing decision, the HKEX required an applicant to disclose the carrying amount of capitalised development costs by project, the remaining amortisation period, and the key assumptions used in the impairment test. The applicant had initially disclosed only a single line item of HKD 250 million; the HKEX required a five-line breakdown by technology platform.

Practical Implications for 2025-2026 Listings

The regulatory environment is becoming more stringent, not less. The HKEX’s 2025 consultation paper on “Strengthening the Listing Regime for Specialist Technology Companies” proposes additional disclosure requirements for R&D capitalisation, including a requirement to disclose the probability-weighted expected future cash flows for each capitalised project.

The Working Capital Sufficiency Test

For applicants with significant capitalised R&D, the working capital sufficiency test under Rule 8.21A becomes a critical hurdle. The HKEX will examine whether the applicant has sufficient cash to fund ongoing R&D without relying on the realisation of capitalised assets. In a 2024 review, the HKEX required an applicant to provide a 12-month cash flow forecast that explicitly excluded any benefit from capitalised R&D (i.e., assuming all future R&D is expensed). The applicant, a robotics company with HKD 80 million in capitalised costs, had to raise an additional HKD 30 million in bridge financing to satisfy the HKEX’s working capital requirement.

The SFC’s Enforcement Risk

The SFC has signalled that it will take a more aggressive stance on R&D accounting in prospectuses. In its 2025 “Enforcement Priorities” statement, the SFC flagged “aggressive capitalisation of development costs” as a key focus area for prospectus review. The SFC’s power to suspend trading or seek a court order for rescission under Section 298 of the SFO means that an incorrect capitalisation policy can have existential consequences for a listing.

Actionable Takeaways

1. Conduct a project-by-project HKAS 38 assessment before engaging the sponsor, documenting technical feasibility with third-party validation for each capitalised project, particularly for pre-revenue biotech and specialist technology applicants.
2. Maintain contemporaneous time-sheets and cost allocation records for all R&D personnel, as the HKEX and SFC will reject capitalisation based on estimated or retrospective allocations.
3. Prepare a sensitivity analysis showing the impact on reported profit if all capitalised R&D were expensed, as this is now a standard HKEX query in the review process.
4. Engage an external technical expert to verify the technical feasibility of each capitalised project, and ensure the expert’s report is included in the sponsor’s due diligence file.
5. Disclose the carrying amount of capitalised development costs by project, the remaining amortisation period, and the key assumptions in the impairment test, as the HKEX now expects granular disclosure beyond a single line item.